factual
Biotech capital structure yields low success rates
Guo describes traditional biotech as a structure where great firms find principal investigators, own about 40 percent of the company, and assemble candidates that mostly fail, producing a very different distribution of outcomes than a software-like model.
factualpending
Speaker
Sarah GuoEvidence Quote
“they own 40% of the company and they're kind of assembling these things, turning them into candidates, but most of it doesn't work.”
Created: 11/17/2026, 6:50:18 AM
Your notes
Loading notes...